SG146643A1 - Treating or preventing restless legs syndrome using prodrugs of gaba analogs - Google Patents

Treating or preventing restless legs syndrome using prodrugs of gaba analogs

Info

Publication number
SG146643A1
SG146643A1 SG200806876-9A SG2008068769A SG146643A1 SG 146643 A1 SG146643 A1 SG 146643A1 SG 2008068769 A SG2008068769 A SG 2008068769A SG 146643 A1 SG146643 A1 SG 146643A1
Authority
SG
Singapore
Prior art keywords
prodrugs
treating
restless legs
legs syndrome
gaba analogs
Prior art date
Application number
SG200806876-9A
Other languages
English (en)
Inventor
Ronald W Barrett
Daniel M Canafax
Original Assignee
Xenoport Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenoport Inc filed Critical Xenoport Inc
Publication of SG146643A1 publication Critical patent/SG146643A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG200806876-9A 2003-09-17 2004-09-17 Treating or preventing restless legs syndrome using prodrugs of gaba analogs SG146643A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US50417203P 2003-09-17 2003-09-17
US50472603P 2003-09-18 2003-09-18
US51227903P 2003-10-17 2003-10-17
US53849504P 2004-01-22 2004-01-22

Publications (1)

Publication Number Publication Date
SG146643A1 true SG146643A1 (en) 2008-10-30

Family

ID=34382174

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200806876-9A SG146643A1 (en) 2003-09-17 2004-09-17 Treating or preventing restless legs syndrome using prodrugs of gaba analogs

Country Status (15)

Country Link
US (1) US8114909B2 (zh)
EP (1) EP1677812A4 (zh)
JP (1) JP5107576B2 (zh)
KR (1) KR101157436B1 (zh)
CN (1) CN1871021B (zh)
AU (1) AU2004274002B2 (zh)
BR (1) BRPI0414481A (zh)
CA (1) CA2538802C (zh)
IL (2) IL174282A (zh)
MX (1) MXPA06003043A (zh)
NO (1) NO20061655L (zh)
NZ (2) NZ579515A (zh)
SG (1) SG146643A1 (zh)
WO (1) WO2005027850A2 (zh)
ZA (1) ZA200602182B (zh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048917B2 (en) * 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7674482B2 (en) * 2002-08-27 2010-03-09 Targeted Medical Pharma Inc. Method and compositions for potentiating pharmaceuticals with amino acid based medical foods
US7025745B2 (en) * 2002-10-07 2006-04-11 Advanced Cardiovascular Systems, Inc. Method of making a catheter balloon using a tapered mandrel
CA2537837A1 (en) * 2003-09-11 2005-03-24 Xenoport, Inc. Treating and/or preventing urinary incontinence using prodrugs of gaba analogs
JP4308263B2 (ja) * 2003-10-14 2009-08-05 ゼノポート，インコーポレイティド γ−アミノ酪酸アナログの結晶形
US20050209319A1 (en) * 2004-03-18 2005-09-22 Xenoport, Inc. Treatment of local pain
WO2006050514A1 (en) 2004-11-04 2006-05-11 Xenoport, Inc. Gabapentin prodrug sustained release oral dosage forms
US7330122B2 (en) 2005-08-10 2008-02-12 Remotemdx, Inc. Remote tracking and communication device
US20070049626A1 (en) * 2005-08-26 2007-03-01 Tran Pierre V Treating premature ejaculation using gabapentin and pregabalin prodrugs
US7737841B2 (en) 2006-07-14 2010-06-15 Remotemdx Alarm and alarm management system for remote tracking devices
CN101652133A (zh) * 2006-12-08 2010-02-17 克塞诺波特公司 Gaba类似物的前药用于治疗疾病的用途
US20080206332A1 (en) * 2007-01-11 2008-08-28 Kidney David J Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
WO2008157408A2 (en) * 2007-06-15 2008-12-24 Xenoport, Inc. Use of prodrugs of gaba analogs, antispasticity agents, and prodrugs of gaba b receptor agonists for treating spasticity
EP2192916A4 (en) * 2007-08-23 2012-04-04 Univ Leland Stanford Junior MODULATION OF SYNAPTOGENESIS
WO2009094563A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-b-methyl-hexanoic acids and methods of use
US7868043B2 (en) 2008-01-25 2011-01-11 Xenoport, Inc. Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
CA2706575C (en) * 2008-01-25 2015-07-14 Xenoport, Inc. Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs
US8299291B2 (en) 2008-08-07 2012-10-30 Xenoport, Inc. Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
US7989641B2 (en) 2008-08-07 2011-08-02 Xenoport, Inc. Methods of synthesizing N-hydroxysuccinimidyl carbonates
TW201032792A (en) * 2009-03-02 2010-09-16 Astellas Pharma Inc Package of solid pharmaceutical preparation
NZ594648A (en) * 2009-03-03 2013-12-20 Xenoport Inc Sustained release oral dosage forms of an r-baclofen prodrug
NZ594952A (en) * 2009-03-06 2013-10-25 Xenoport Inc Oral dosage forms having a high loading of a gabapentin prodrug
US20150158809A9 (en) 2013-02-26 2015-06-11 Xenoport, Inc. Method of making 1-(acyloxy)-alkyl carbamate compounds
CN105169266A (zh) * 2015-10-02 2015-12-23 陈爱华 一种用于治疗不安腿综合征的药物制剂
CN105777586A (zh) * 2016-04-14 2016-07-20 安徽省逸欣铭医药科技有限公司 S（+）氨己烯酸酯衍生物及其制备方法和用途
FI3752141T3 (fi) 2018-02-15 2024-07-02 Intrabio Ltd Asetyylileusiini käytettäväksi levottomat jalat –oireyhtymän hoidossa
WO2020074160A1 (en) 2018-10-10 2020-04-16 Curovir Ab Condensed pyrimidine or pyridazine derivatives as antiviral agents
WO2020165633A1 (en) * 2019-02-11 2020-08-20 Glenmark Pharmaceuticals Limited A pharmaceutical composition of gabapentin enacarbil or salt thereof

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2996431A (en) 1953-12-16 1961-08-15 Barry Richard Henry Friable tablet and process for manufacturing same
US3402240A (en) 1957-06-25 1968-09-17 Pfizer & Co C Medicinal tablet and process of making same
US3139383A (en) 1961-06-26 1964-06-30 Norton Co Encapsulated time release pellets and method for encapsulating the same
US3962414A (en) 1972-04-27 1976-06-08 Alza Corporation Structured bioerodible drug delivery device
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3811444A (en) 1972-12-27 1974-05-21 Alza Corp Bioerodible ocular device
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
DE2336218C3 (de) 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
US3992518A (en) 1974-10-24 1976-11-16 G. D. Searle & Co. Method for making a microsealed delivery device
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4079038A (en) 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
US4066747A (en) 1976-04-08 1978-01-03 Alza Corporation Polymeric orthoesters housing beneficial drug for controlled release therefrom
US4070347A (en) 1976-08-16 1978-01-24 Alza Corporation Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4434153A (en) 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
US4421736A (en) 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
US4721613A (en) 1982-12-13 1988-01-26 Alza Corporation Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use
US4820523A (en) 1986-04-15 1989-04-11 Warner-Lambert Company Pharmaceutical composition
US4752470A (en) 1986-11-24 1988-06-21 Mehta Atul M Controlled release indomethacin
US4816263A (en) 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
US4853229A (en) 1987-10-26 1989-08-01 Alza Corporation Method for adminstering tiny pills
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
DE3928183A1 (de) 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
US5084169A (en) * 1989-09-19 1992-01-28 The University Of Colorado Foundation, Inc. Stationary magnetically stabilized fluidized bed for protein separation and purification
US5084479A (en) 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US5827819A (en) 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
AU9137091A (en) 1990-11-27 1992-06-25 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
RU94046105A (ru) 1992-05-20 1997-06-20 Нортвестерн Юниверсити (Us) АНАЛОГИ γ -АМИНОМАСЛЯНОЙ КИСЛОТЫ И L-ГЛУТАМИНОВОЙ КИСЛОТЫ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
US6287598B1 (en) 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
PL328432A1 (en) 1996-02-07 1999-02-01 Warner Lambert Co Novel cyclic amino acids as pharmaceutic agents
BR9708200A (pt) 1996-03-14 1999-07-27 Warner Lambert Co Aminoácidos cíclicos substituídos como agentes farmacéuticos
CZ287598A3 (cs) 1996-03-14 1999-02-17 Warner-Lambert Company Přemostěné cyklické aminokyseliny
KR100491282B1 (ko) 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
US6375987B1 (en) 1996-10-01 2002-04-23 Gattefossé, S.A. Process for the manufacture of pharmaceutical composition with modified release of active principle comprising the matrix
EP0937032B1 (en) 1996-10-23 2007-05-09 Warner-Lambert Company LLC Substituted gamma aminobutyric acids as pharmaceutical agents
SE509618C2 (sv) 1997-03-06 1999-02-15 Goeran Blomqvist Farmaceutisk komposition för behandling av s k restless legs
AU8668598A (en) 1997-08-20 1999-03-08 University Of Oklahoma, The Gaba analogs to prevent and treat gastrointestinal damage
BR9813284B1 (pt) 1997-10-27 2012-08-21 aminoácidos cìclicos e derivados dos mesmos úteis como agentes farmacêuticos e composição farmacêutica.
CN1210268C (zh) 1997-12-16 2005-07-13 沃尼尔·朗伯公司 ((环)烷基取代的)－γ－氨基丁酸衍生物(=GABA类似物),其制备和在治疗神经病中的用途
US6545022B1 (en) * 1997-12-16 2003-04-08 Pfizer Inc. 4(3)substituted-4(3)-aminomethyl-(thio)pyran or piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
CA2304974C (en) 1997-12-16 2005-10-25 Warner-Lambert Company 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
AU2463099A (en) 1998-01-23 1999-08-09 Warner-Lambert Company Gabapentin and its derivatives for the treatment of muscular and skeletal pain
US6114326A (en) 1998-03-27 2000-09-05 Pharmacia & Upjohn Company Use of cabergoline in the treatment of restless legs syndrome
CA2322558C (en) 1998-05-26 2006-04-11 Warner-Lambert Company Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
AUPP396998A0 (en) 1998-06-09 1998-07-02 University Of Melbourne, The A method for increasing the permeability of wood
FR2779651B1 (fr) 1998-06-16 2001-04-20 Gattefosse Ets Sa Procede pour la fabrication de comprimes a liberation prolongee de principe(s) actif(s) presentant une cinetique de dissolution d'ordre zero
US6171615B1 (en) 1998-07-06 2001-01-09 Gattefoss{acute over (e)} Sustained release theophylline formulations, excipient systems and methods of production
JP2002524551A (ja) 1998-09-14 2002-08-06 ワーナー−ランバート・カンパニー 分枝鎖アルキルピロリジン−３−カルボン酸
CA2344407C (en) 1998-10-16 2007-01-09 Warner-Lambert Company Method for the treatment of mania and bipolar disorder
WO2000031020A1 (en) 1998-11-25 2000-06-02 Warner-Lambert Company Improved gamma amino butyric acid analogs
EP1031350A1 (en) 1999-02-23 2000-08-30 Warner-Lambert Company Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
US7164034B2 (en) * 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
EP1202725B1 (en) 1999-07-22 2007-04-11 University Of Rochester Method of treating symptoms of hormonal variation, including hot flashes
MXPA02008101A (es) 2000-02-22 2005-04-19 Cellegy Canada Inc Metodos y composiciones para mejorar el sueno.
GB2362646A (en) 2000-05-26 2001-11-28 Warner Lambert Co Cyclic amino acid derivatives useful as pharmaceutical agents
ATE390133T1 (de) 2000-06-26 2008-04-15 Warner Lambert Co Gabapentinanaloga für schlafstörungen
GB2365425A (en) 2000-08-01 2002-02-20 Parke Davis & Co Ltd Alkyl amino acid derivatives useful as pharmaceutical agents
DE10043321B4 (de) 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
US6900192B2 (en) 2000-10-06 2005-05-31 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
AU2002243204A1 (en) 2000-10-06 2002-06-11 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
AU2002211863A1 (en) 2000-10-06 2002-04-15 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
AR031152A1 (es) 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
GB2368579A (en) 2000-10-31 2002-05-08 Parke Davis & Co Ltd Azole pharmaceutical agents
AU2002239257A1 (en) 2000-11-17 2002-06-03 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US20020165246A1 (en) * 2001-03-05 2002-11-07 Andrew Holman Administration of sleep restorative agents
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
EP1412324A4 (en) 2001-06-11 2004-09-29 Xenoport Inc AMINO ACID CONJUGATES THAT RESULT IN GABA ANALOGA LASTING SYSTEMIC CONCENTRATIONS
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
AU2002345664C1 (en) * 2001-06-11 2008-03-06 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof
WO2002100349A2 (en) 2001-06-13 2002-12-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of the parathroid hormone-2 (pth2) receptor to screen for agents to treat pain
MXPA04002709A (es) 2001-09-24 2005-06-06 Johnson & Johnson Derivados articonvulsivos utiles para el tratamiento del sindrome de extremidades inquietas y trastorno periodico del movimiento de extremidades.
WO2003037329A1 (en) 2001-10-31 2003-05-08 Pfizer Products Inc. Nicotinic acetylcholine receptor agonists in the treatment of restless legs syndrome
AU2002316231A1 (en) * 2002-02-19 2003-09-29 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
TW555626B (en) * 2003-01-24 2003-10-01 Smoos Tool Co Ltd Method for treating a collar surface and its product
JP4308263B2 (ja) 2003-10-14 2009-08-05 ゼノポート，インコーポレイティド γ−アミノ酪酸アナログの結晶形
WO2006050514A1 (en) * 2004-11-04 2006-05-11 Xenoport, Inc. Gabapentin prodrug sustained release oral dosage forms

Also Published As

Publication number Publication date
US20050192353A1 (en) 2005-09-01
US8114909B2 (en) 2012-02-14
WO2005027850A2 (en) 2005-03-31
EP1677812A2 (en) 2006-07-12
KR101157436B1 (ko) 2012-07-05
CA2538802A1 (en) 2005-03-31
IL174282A0 (en) 2006-08-01
IL174282A (en) 2012-12-31
BRPI0414481A (pt) 2006-11-14
AU2004274002B2 (en) 2011-04-28
CA2538802C (en) 2015-01-27
NZ545989A (en) 2009-10-30
ZA200602182B (en) 2012-07-25
IL200687A0 (en) 2011-08-01
CN1871021B (zh) 2010-07-28
JP5107576B2 (ja) 2012-12-26
NO20061655L (no) 2006-06-15
MXPA06003043A (es) 2006-05-31
WO2005027850A3 (en) 2005-06-16
NZ579515A (en) 2011-09-30
AU2004274002A1 (en) 2005-03-31
CN1871021A (zh) 2006-11-29
KR20060106815A (ko) 2006-10-12
EP1677812A4 (en) 2010-03-24
JP2007511464A (ja) 2007-05-10

Similar Documents

Publication Publication Date Title
SG146643A1 (en) Treating or preventing restless legs syndrome using prodrugs of gaba analogs
HK1085140A1 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
NO20061625L (no) Behandling og/eller forhindring av urininkontinens ved bruk av prolegemidler av gaba analoger
NO20045240L (no) Transepikutan administrasjonsform for a behandle restless legs syndromet
HK1086186A1 (en) Use of spongosine (2-methoxyadenosein) for preparing pharmaceutical for the treatment of pain
WO2007027477A3 (en) Treating vulvodynia using prodrugs of gaba analogs
MX2009005114A (es) Uso de los profarmacos gabapentina y pregabalina para tratar el tinnitus.
CY1110407T1 (el) Συνθεση για χορηγηση σιδηρου για την θεραπεια του συνδρομου σπασμωδικου σκελους
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
MXPA05010515A (es) Tratamiento o prevencion de sofocos calientes utilizando profarmacos de analogos de gaba.
DE60323765D1 (de) Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
MY166631A (en) Orally administrable composition for improving skin quality
WO2006014864A3 (en) Methods and compositions for reducing c-reactive protein
EA200801731A1 (ru) Составы и способы лечения тробмоцитемии
MX2009011817A (es) Formulaciones de aminoacido n-halogenado que contienen acido alifatico.
GB2452142A (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
EA200501591A1 (ru) Фармацевтическая комбинация для лечения мышечной спастичности и/или боли
MXPA04006269A (es) Composicion farmaceutica que comprende un inhibidor de alfa-glucosidasa y acido 4-oxobutanoico y uso de la misma para tratamiento de diabetes.
MXPA04006675A (es) Composicion farmaceutica que comprende glitazona y acido 4-oxobutanoico y uso de la misma para tratamiento de diabetes.
HU0101978D0 (en) Pharmaceutical formulations, sets and compositions useful to recover deficiency caused by side effects of pharmaceutical treatments
UA50328A (uk) Спосіб лікування атоній передшлунків великої рогатої худоби